- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03968640
Efficacy of Coenzyme Q10 Supplementation on Multi-Organ Dysfunction in Severely Burned Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Burns represent one of the most excruciating and devastating battlefield injuries. Based on estimates reported in 2010, burn injuries account for 603,000 visits to US emergency departments and 50,000 hospital admissions each year. The annualized cost of these hospitalizations totals $1 billion. Despite recent advances in acute critical care, the damage that occurs to organs and systems (e.g., heart, liver, kidney, lung, and immune cells) in the sub-acute phase of severe burn injury remains a major challenge to achieving further reductions in mortality and improvements in the long-term clinical and functional outcomes of burn.
The treatment proposed in this study targets the mitochondria, organelles that are crucial for the survival and function of every cell type within the body. Known as the power plants of cells, the mitochondria generate energy and also function as critical regulators of cellular life, death, and inflammation. Burn injury damages the mitochondria in cells close to and distant from the injury site. This, in turn, complicates the patient's critical illness by causing multiple organ dysfunction. The mitochondria, therefore, pose a plausible potential target to further improve the clinical outcome of burn patients. Nonetheless, therapies that target the mitochondria have not yet been studied in burn patients.
CoQ10 is an essential nutrient that is vital to the function and integrity of the mitochondria. CoQ10 deficiency causes mitochondrial dysfunction and thereby induces dysfunction in multiple organs, including liver, heart, immune cells (i.e., white blood cells), brain, and muscle. In a pilot clinical study of CoQ10, we showed that burn injury causes CoQ10 deficiency, which is reversed by CoQ10 supplementation. In our preclinical study in mice, CoQ10 administration prevented mitochondrial damage, systemic inflammation, and metabolic dysfunction in burned animals, and improved survival and bacterial killing activity in animals with severe infection. Our data indicate that CoQ10 deficiency caused by burn injury may worsen the patient's clinical condition. Since CoQ10 supplementation is capable of reversing CoQ10 deficiency, which, in turn, may prevent mitochondrial damage and subsequent dysfunction of multiple organs, it is a plausible therapy for preventing mortality and promoting recovery in burn patients.
Two hundred ninety eligible burn patients admitted to any of the 15 military and civilian hospitals participating in this study will be enrolled within 48 hours after severe burn injury and randomly assigned to either CoQ10 (n=150) or Placebo (n=150) group. The safety and the efficacy of CoQ10 on multiple organ dysfunction and death, length of hospital stay, mitochondrial damage, and muscle wasting will be studied in comparison with Placebo.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Herb Phelan, MD
- Phone Number: (214) 648-6841
- Email: Herb.Phelan@UTSouthwestern.edu
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- UTMB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years and older
- Burn patients with 20% or greater of total body surface area (TBSA) burn and equal to or less than 70% TBSA burn
- Capable of receiving routine oral, enteral nutrition, or a combination of routine oral and enteral nutrition
- Enrolled within 72 hours after burn injury
- Patient or legally authorized representative (LAR) who is capable of giving full informed consent
- Anticipated hospital stay: 2 weeks or more
Exclusion Criteria:
- Patients with liver disease (bilirubin greater than 3 or diagnosis of liver cirrhosis) at the time of admission, hyperthyroidism that currently requires treatment, diagnosis of chronic heart failure, chronic renal failure requiring hemodialysis, malignancy currently undergoing treatment, or history of cancer or hematological malignancy treatment within 5 years
- History of HIV or AIDS
- Presence of concurrent injuries apart from burn injury that may produce long-term disabilities (e.g., spinal cord injury, anoxic brain injury)
- Participation in another research study that may confound the results of this study in the opinion of the site principal investigator
- Pregnant women
- Prisoners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CoQ10 group
The patients assigned to the CoQ10 group will receive the loading dose of CoQ10 (1,800 mg/day) for 4 weeks followed by the maintenance dose of CoQ10 (600 mg/day) for 8 weeks or until hospital discharge, whichever comes first.
|
The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12.
The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first.
Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
Other Names:
|
Placebo Comparator: Placebo
Allocation-concealed placebo will be used as an appropriate control.
|
The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12.
The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first.
Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the efficacy of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients in the mitigation of multi-organ dysfunction (MODS)
Time Frame: 12 weeks
|
Evaluated by the number of the six events (i.e., renal, respiratory, cardiovascular and liver dysfunction, coagulopathy, and death
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
The six individual organ systems comprising the MODS score and their times of occurrences.
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
The weighted composite score of the six constituents
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
The maximum total Sequential Organ Failure Assessment (SOFA) score
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
The maximum SOFA score for each organ
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
AUC of total SOFA score (score x days)
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
AUC of SOFA score for each organ (score x days)
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
Delirium (CAM-ICU) (number of days)
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
Length of hospital stay (number of days)
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
Sepsis (Sepsis-3) (number of incidence)
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
Septic Shock (Sepsis-3) (number of incidence)
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
Plasma mitochondrial DNA (4 blood collections)
|
12 weeks
|
Evaluate the effect of reduced form CoQ10 (ubiquinol) supplementation in severely burned adult patients on the following clinical outcome events and biochemical measurements in plasma and urine.
Time Frame: 12 weeks
|
3-Methylhistidine (3-MH) and creatinine in urine (a biomarker of muscle wasting)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Herb Phelan, MD, University of Texas
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABA-MCTG-0005
- W81XWH-18-2-0030 (Other Grant/Funding Number: USAMRAA)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Organ Failure
-
Centre Hospitalier de CornouailleCompletedOrgan Failure, MultipleFrance
-
University Hospital, CaenNot yet recruitingOrgan Failure, Multiple
-
University of LeicesterZimmer Biomet; British Heart Foundation; National Health Service, United KingdomWithdrawnSepsis | Inflammation | Organ Failure, MultipleUnited Kingdom
-
Taipei Medical University WanFang HospitalWithdrawn
-
Azienda Socio Sanitaria Territoriale degli Spedali...Università degli Studi di BresciaCompletedCitrulline | Organ Failure, Multiple | Intra Abdominal Pressure | Gastro Intestinal Failure
-
Hospital Sant Joan de DeuFundació Sant Joan de Déu; Spanish National Health SystemCompletedInflammatory Response | Multi-organ FailureSpain
-
University Hospital, RouenNot yet recruitingSeptic Shock | Intermittent Fasting | Organ Failure, Multiple
-
University Medical Center GroningenNot yet recruitingCritically Ill | Organ Failure, Multiple
-
University of PittsburghCompletedPancreatitis | Organ Failure, Multiple
-
Advanced Perfusion DiagnosticsCEISOCompletedMultiple Organ Dysfunction SyndromeFrance
Clinical Trials on CoQ10
-
Mélanie PlourdeUnknown
-
Beth Israel Deaconess Medical CenterKaneka Medical America LLCCompleted
-
University of RochesterNational Institute of Neurological Disorders and Stroke (NINDS)CompletedParkinson DiseaseUnited States
-
Lahey ClinicCompletedNeurological Disorders | Progressive Supranuclear PalsyUnited States
-
Reproductive Endocrinology Associates of CharlotteCompletedAneuploidy | Mitochondrial DNAUnited States
-
Medical University of GdanskNot yet recruitingExercise Training | Ischemic Preconditioning | Coenzyme Q DeficiencyPoland
-
VISUfarma SpAUnknown
-
Maimónides Biomedical Research Institute of CórdobaUnknownCoenzyme Q10 on Athero-thrombosis in APS PatientsSpain
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Memorial Medical CenterUnited States Department of DefenseCompleted